Geron Corporation (GERN) saw its stock price surge 5.50% in Wednesday's trading session, despite reporting mixed results for the third quarter of 2025. The biotechnology company's financial performance, while showing some improvements, fell short of some analysts' expectations.

According to the earnings summary, Geron reported a quarterly adjusted loss of 3 cents per share, in line with analysts' expectations but higher than the 4 cents loss reported in the same quarter last year. Revenue rose 67.1% to $47.23 million, falling short of the $52.88 million expected by analysts. Despite these mixed results, the company's strategic initiatives and market expansion plans seem to have instilled confidence in investors.

The stock's rally appears to be fueled by continued positive sentiment from Wall Street analysts. TD Cowen analyst Tara Bancroft maintained a Buy rating on Geron with a price target of $4.00. Similarly, Needham analyst Gil Blum reiterated a Buy rating, citing the company's strong financial position despite a dip in Rytelo sales. The current average analyst rating on Geron shares is "buy," with Wall Street's median 12-month price target at $4.00, representing a significant upside potential from its last closing price. This continued analyst confidence, coupled with the company's future prospects, seems to have overshadowed the mixed quarterly results, driving the stock's impressive intraday gain.